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ABSTRACT
THE IMPACT OF GESTATIONAL DIABETES ON MATERNAL AND CORD BLOOD
LIPIDS AMONG PRENATAL CARE PATIENTS IN WESTERN MA
SEPTEMBER 2012
PREETHI RAJ, B.A. BIOLOGY, CLARK UNIVERSITY
M.S. EPIDEMIOLOGY, UNIVERSITY OF MASSACHUSETTS AMHERST
Directed by: Dr. Brian Whitcomb, PhD

Gestational diabetes mellitus (GDM), a pregnancy-induced metabolic disorder that affects
2-10% of pregnancies poses future risk for diabetes mellitus (DM) and cardiovascular disease in
mother and child. However, few prospective studies have examined the effect of GDM on altered
maternal and cord blood lipids, specifically HDL, LDL, triglycerides, and total cholesterol, both
during and after pregnancy. We have evaluated the association between GDM and lipid
metabolism in pregnant mothers and their infants using data from a prospective cohort study
conducted at Baystate Medical Center’s Wesson Women and Infant’s Unit. GDM was assessed
prenatally by 3-hr GTT blood samples and was confirmed by obstetrician review. Lipids were
assessed via fasting and non-fasting blood samples obtained during 3-hr GTTs performed at 2428 weeks of gestation and 6-8 weeks post-partum. Data for covariates were collected via an
interview form administered at the time of recruitment. We used multivariable linear regression
to evaluate the association between GDM status and maternal lipids during and after pregnancy
as well as cord lipids. These study results inform future research on GDM as a risk factor for
future metabolic disorders in mother and child.
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CHAPTER 1
INTRODUCTION
Diabetes mellitus is defined as a metabolic disorder in which a person experiences high
levels of blood sugar either due to insufficient insulin production (Type I) or sensitivity (Type
II). Gestational diabetes mellitus (GDM) is distinguished from diabetes mellitus as the advent of
Type II-like, impaired musculoskeletal insulin sensitivity during pregnancy and has been
recently reported to affect 18% of pregnancies due to changes in diagnostic criteria compared to
previous prevalence estimates of 2-10% of pregnancies (1). Women diagnosed with gestational
diabetes have a 35% to 60% chance of developing diabetes in the next 10-20 years (1) and the
estimated healthcare costs are high. In the year 2007 alone, GDM increased national medical
costs by $636 million-- $596 for maternal costs and $40 million for neonatal costs (2). These
costs can only be expected to rise.
Hyperlipidemia, the condition of elevated blood lipids, is of concern because of its
association with metabolic syndrome, a complex collection of metabolic disorders including
obesity, hypertension, hyperlipidemia, insulin resistance, and elevated glucose concentrations
(3). Metabolic syndrome is currently estimated to affect 34% of the United States population and
is known to increase an individual’s future risk for cardiovascular disorders (4). For a formal
diagnosis of metabolic syndrome, 3 out of 5 of the following criteria must be met: waist
circumference>88cm; HDL cholesterol less than 40 mg/dL; serum triglyceride levels ≥150
mg/dL; systolic blood pressure >130 mm/Hg or diastolic blood pressure ≥ 85 mm/Hg, and a
fasting blood glucose level ≥ 100 mg/dL (5). Physiologic changes during pregnancy result in a
naturally transient hyperlipidemic and hyperglycemic state, and can often serve as an antecedent
to the development of Type II diabetes and cardiovascular disease (6).
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Established risk factors for elevated blood lipid levels during pregnancy include family
history of hypercholesterolemia (7) and maternal BMI (8). Maternal diet during pregnancy has
also been implicated in altering the amounts of endogenous lipids in the mother that are probably
conferred to the child (9). Additionally, gestational diabetes mellitus has been proposed as a
possible risk factor for elevated maternal and cord blood lipids due to its enhancement of
existing altered metabolism during pregnancy (10).
The distinctive hormonal milieu of pregnancy is thought to cause insulin resistance,
promoting oxidative stress which encourages the development of endothelial dysfunction and
future cardiometabolic risk for both mother and child (11, 12, 13, 14). Excess endogenous
glucose during the GDM pregnancy has been proposed to induce an imbalance of HDL and LDL
particles in maternal blood circulation, in which LDL dominates (6, 10, 15). Furthermore,
accumulation of body fat in early pregnancy and subsequent lipolytic activity in the third
trimester, combined with an increased maternal-fetal gradient, have been hypothesized to cause
the accelerated transfer of various cholesterol particles from mother to child (16, 17, 18).
Although these physiologic mechanisms are not definitive, they provide a conceptual framework
from which GDM can affect maternal and cord blood lipids.
Few epidemiologic studies (21, 22, 23, 24, 25, 26, 27, 28, 31) have examined the effect of
GDM on lipid levels during pregnancy and those that have produced conflicting results. No
prospective longitudinal investigations have evaluated whether women experience blood lipid
alterations subsequent to GDM diagnosis. Studies are needed to explore the possibility of GDM
conferring future metabolic risk for mother and child postpartum.
We therefore conducted a prospective study among pregnant women seen at Baystate
Medical Center in Springfield, MA to assess the effect of their GDM status on their maternal
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lipids both during and after pregnancy as well as cord blood lipids after delivery. Study findings
will help to elucidate whether the effects of hyperglycemia during pregnancy are long-standing
for mother and child.
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CHAPTER 2
PHYSIOLOGY OF GDM AND LIPID OUTCOMES
Gestational diabetes has been shown to alter maternal and cord blood lipids
simultaneously, such that cord blood lipid levels reflect maternal blood lipid levels. Previous
studies comparing maternal blood and cord blood serum levels of adiponectin, a protein hormone
involved in glucose regulation and fatty acid metabolism, provide conflicting explanations of
how maternal and cord blood serum is related. While one study found no correlation between
maternal blood and cord blood serum adiponectin levels in healthy mothers along with higher
adiponectin levels in cord blood, and significant correlations between cord blood adiponectin
levels and neonatal birthweight (19), another study found maternal blood adiponectin levels to be
independent predictors of cord blood adiponectin levels, regardless of whether women had GDM
or not (20). These findings warrant separate consideration of maternal and cord blood serum
lipids in GDM and non-GDM women.

2.1. Physiology of GDM and Maternal Blood Lipid Relationship
The mechanism for how GDM affects maternal blood lipids requires further elucidation,
however, several hypotheses exist. Pregnancy-induced changes in steroid hormones, estrogen
and progesterone, cortisol, human chorionic somatolactotropin (HCS), and sex hormone binding
globulin (SHBG) are further disrupted in GDM resulting in lower than normal estrogen levels
accompanied by insulin resistance, or the inability to utilize insulin. Insulin resistance in turn
causes inflammation, endothelial dysfunction, and the formation of reactive oxygen species,
markers of oxidative stress (11, 12, 13, 14). Oxidative stress during pregnancy can cause an
imbalance of HDL and LDL particles, resulting in predominant amounts of the latter, less
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favorable form of cholesterol (10). This phenomenon is particularly enhanced during gestational
diabetes where (excess) glucose acts as a principal oxidative substrate used by the fetus for
growth (10). Secondly, excess endogenous glucose in pregnant woman stimulates the liver to
metabolize fats into cholesterol, hence resulting in elevated lipid levels (15). Thirdly, while the
first and second trimester of normal pregnancy is characterized by increased accumulation of
maternal fat stores, breakdown and conversion of maternal fats and cholesterol for growth of the
fetus occurs in the third trimester. Pronounced insulin resistance in GDM, however, inhibits third
trimester lipoprotein lipase (LPL) enzyme activity, allowing for higher levels of endogenous
triglycerides to which both mother and child are vulnerable (14). Lastly, the increase of lipids
during pregnancy in response to GDM exposure may be a precursor to sustained postpartum
dyslipidemia, much like how GDM is considered a precursor to future, if not immediate
postpartum diabetes (21). Overall, the mechanisms for how GDM causes elevated maternal
blood lipids are not clearly understood, yet, the often synchronous occurrence of the two purports
a possible causal link.
2.2. Physiology of GDM and Cord Blood Lipid Relationship
Diabetes during pregnancy has been shown to increase the transfer of non-esterified fatty
acids (NEFAs), total cholesterol, triglycerides, phospholipids, and cholesterol esters from the
mother to her child. This is possibly due to an increased maternal-fetal gradient, or increased
permeability of blood and organic matter between the mother and child across the placental
barrier (19, 22). Maternal body fat accumulation during the early stages of pregnancy allows for
the storage of long-chain polyunsaturated fatty acids, which the pregnant woman obtains via diet
and her own metabolism (20). Towards the end of the pregnancy the pregnant woman
experiences increased lipolytic (“fat breaking”) activity in these accumulated fat cells, which are
converted into cholesterol, as well as NEFAs, glycerol, and ketone bodies for fetal growth. The
5

degree of maternal blood lipids found in GDM cord vein blood is dependent upon several factors
such as fetal consumption, efficient or impaired placental transfer, and/or altered fetal
metabolism (14). Accelerated fetal growth in the 3rd trimester demands large and frequent
transfers of nutrients from the mother. In women with GDM, it has been therefore hypothesized
that the excess presence of glucose within endogenous maternal blood, characteristic of GDM,
provides ample opportunity for elevated levels of glucose and cholesterol to cross the placental
barrier into the cord blood, resulting in metabolically challenged babies (20). Excess glucose
conferred to the child produces fetal hyperinsulinemia (12, 13), which further alters the child’s
cardiometabolic profile. In sum, during pregnancy the mother’s body acts as an exposure for
their child, such that the metabolic repercussions of GDM and high cholesterol levels could
possibly affect the child.
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CHAPTER 3
EPIDEMIOLOGY OF GDM AND LIPID OUTCOMES
3.1. Epidemiology of GDM and Maternal Blood Lipid Relationship
Several epidemiologic studies have specifically examined the impact of GDM on
maternal blood lipids (21, 23, 24, 25, 26, 27, 28). Seven prospective cohort studies, by Sokup et.
al (2012), Akinci et. al (2011), Marseille-Tremblay et al (2008), Lauenborg et al. (2005), Sobki
et al. (2004), Couch et. al (1998), and Meyers-Seifer et al. (1996) have considered maternal
blood lipids and GDM while addressing the role of cardiovascular biomarkers in the
development of metabolic syndrome in women several years after they had GDM. These studies
have generally observed modest differences in blood lipids comparing women with and without
GDM, with women with GDM have slightly higher levels of serum total cholesterol, LDL, and
HDL (measured in units of mmol/L or mg/dL, where 1 mmol=38.67 mg/dL) and triglycerides,
(also measured in units of mmol/L or mg/dL, where 1 mmol=88.57 mg/dL) (29, 30).
Sokup et al. (21) conducted a prospective post-pregnancy cohort study in Poland in 2011,
where they sought to investigate whether women with a previous history of gestational diabetes
from 2005-2007 were at a higher and premature risk for elevated triglyceride levels and glucose
dysregulation. The authors defined their exposure groups as 125 prior GDM pregnancies and 40
prior normal pregnancies. Diagnosis of GDM was made using 50g and 75g oral glucose
tolerance tests and according to World Health Organization criteria. Blood samples that were
profiled for total cholesterol, TG, LDL, and HDL were obtained during post-partum visits
between 2-24 months after the index pregnancy. While none of the women were diet-managed or
on glucose or lipid-lowering medications during their pregnancy, most of the women were
breastfeeding at the time of their postpartum visit. The authors found the following median
values in previous GDM vs. non-GDM mothers (in mg/dL): slightly higher TC: (195.67 vs.
7

176.34, p=0.001), slightly higher LDL: (122.58 vs. 99.38 , p=0.001), slightly lower HDL: (59.17
vs. 66.90 , p=0.001), and slightly higher TG: (90.34 vs. 76.17 , p=0.012). In spite of the
statistical significance of these results there is a possibility for the assessment of postpartum
lipids within the first two years of delivery to encompass a varied range of lipid profiles with
respect to time since pregnancy and breastfeeding status.
Similarly, Akinci et. al (23) conducted a prospective post-pregnancy cohort study in
Turkey in 2011where they sought to investigate whether women diagnosed with gestational
diabetes between 2002-2008 were more likely to develop postpartum carbohydrate intolerance,
metabolic syndrome, and exhibit cardiovascular risk factors than women without prior GDM.
Gestational diabetes was diagnosed at 24-28 weeks of pregnancy using Carpenter and Coustan
criteria and, in the case of positive diagnosis, women were prescribed diet control. Postpartum
lipids, such as TC, TG, LDL, and HDL, were evaluated in 1 year intervals with an average
follow-up of approximately 3 years. The authors found the following means for maternal lipids
in GDM vs. non-GDM mothers (in mg/dL): slightly higher TC: (199.15 vs. 175.56, p<0.001),
slightly higher TG: (122.23 vs. 87.68, p=0.006), slightly higher LDL: (123.74 vs. 96.29,
p<0.001), and slightly higher HDL: (51.43 vs. 61.48, p=0.01). Higher BMI values for GDM
mothers may suggest, however, a separate underlying pathophysiologic mechanism to produce
the observed lipids.
Marseille-Tremblay et al. (24) conducted a small prospective, hospital-based cohort study
in Canada in 2008, where they defined their exposure groups as GDM and non-GDM (healthy)
women and their outcome as maternal total cholesterol, TG, LDL, and HDL levels. Their total
enrollment was 14 subjects, with 7 insulin-treated GDM women and 7 non-GDM women. The
authors assessed their GDM exposure by administering an interview to the women on medical
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history around 10 weeks of gestation. The authors assessed maternal lipid outcomes via blood
samples collected at delivery. The authors found the following means±standard errors for
maternal lipids in GDM vs. non-GDM mothers (in mg/dL): slightly higher TC (265.66±23.20
vs. 260.0±17.40, nonsignificant [NS], no p-value provided); slightly higher TG (266.60±43.40
vs. 261.28±41.62, NS, no p-value provided); slightly higher LDL (141.92±16.63 vs.
141.53±17.79, NS, no p-value provided), and slightly lower HDL (63.03±6.19 vs. 69.99±3.48,
NS, no p-value provided). These observed differences, however, were modest and not
statistically significant. Marseille-Tremblay et al. was the only study to examine the effect of
GDM on maternal lipids during gestation as well as after delivery, and the small sample size of
this study challenges interpretation of these null findings.
Lauenborg et al. (25) conducted a prospective, hospital-based cohort study in Denmark in
2005, defining exposure as prior diagnosis of diet-only treated GDM, and the outcome as fasting
serum HDL cholesterol and fasting serum TG. The total enrollment was 1,481, with 481 prior
GDM (cases) and 1000 age matched, healthy, comparison women. GDM exposure was defined
as diagnosis during 1978-1985 and 1987-1996 based on risk factor-based Dutch criteria (31).
The authors assessed fasting HDL and TG levels via fasting morning blood samples during a
median follow-up of 9.8 years after pregnancy. The authors found the following medians for
maternal lipids in GDM vs. non-GDM mothers: In mg/dL; slightly higher TG: 115.14 vs. 88.57,
p<0.0005, and slightly lower HDL: 54.14 vs. 58.0, p<0.0005. These statistically significant pvalues belie the negligible difference between lipids in both groups. This study did not assess
GDM exposure using the standard glucose tolerance test at the time of the study. If there had
been any changes in the women’s GDM status since their initial diagnosis via screening criteria
this method of exposure assessment may not accurately reflect their GDM status during the
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study, hence leading to misclassification of exposure. The efficiency of the Danish screening
criteria that the authors used at the time of the study is, therefore, dependent upon how sensitive
and accurate it was in distinguishing women who truly have GDM from those who do not. These
potential limitations suggest the possibility of study results being biased towards the null.

Sobki et al. (26) conducted a prospective, hospital-based cohort study in Saudi Arabia in
2004, where they sought to examine the effect of gestational diabetes on biomarkers of oxidative
stress and cardiovascular risk in maternal blood samples. GDM was diagnosed during the 22nd28th week of gestation according to National Diabetes Data Group criteria and their exposure
categories consisted of 19 GDM mothers receiving insulin treatment, 27 GDM women managed
by diet, and 40 non-GDM women. Maternal serum samples were obtained during the second
stage of labor. All comparisons of TC, TG, LDL, and HDL levels between diet-treated/ insulintreated GDM women and non-GDM women were not statistically significant. The explanation
for these results is unclear. Obtaining maternal blood samples during the second stage of labor,
however, may provide an altered state of lipids in both GDM and non-GDM mothers, which
would then underestimate any differences, biasing the results towards the null.
In the only study to evaluate the association between GDM and lipids at 37-38 weeks
gestation, Couch et al. (27) conducted a prospective, hospital-based cohort study in Hartford,
Connecticut in 1998, where they defined their exposure groups as GDM and non-GDM (healthy)
women and their outcome as maternal total cholesterol, TG, LDL, and HDL levels. Their total
enrollment was 40 subjects, with 20 diet-managed GDM women and 20 non-GDM women. The
authors assessed their GDM exposure by administering a 1hr-50g glucose tolerance test,
followed by a 3hr GTT, at 24-30 weeks gestation to confirm GDM diagnosis according to
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O’Sullivan and National Diabetes Data Group criteria. Maternal lipid outcomes were assessed
via blood samples collected at 37-38 weeks gestation. The authors found the following means for
maternal lipids in GDM vs. non-GDM mothers (in mg/dL): slightly lower TC: 221.50 vs. 232.46
(NS, no p-value provided), slightly higher TG: 236.38 vs. 177.96 (p≤ .01), slightly higher LDL:
68.76 vs. 46.14 (p< .01), and slightly higher HDL: 58.05 vs. 41.34 (p≤.01). Of these results,
elevated TG, LDL, and HDL levels for GDM women were statistically significant. The use of
older, less conservative, GDM diagnosis criteria and the enrollment of women with GDM who
did not require insulin to maintain glucose control may have biased the study results toward the
null.
The first of two studies to evaluate the association between GDM and postpartum lipids,
Meyers-Seifer et al. (28) conducted a prospective, hospital-based cohort study in Providence,
Rhode Island in 1996, defining exposure as prior diagnosis of GDM, and outcome as fasting
maternal blood serum total cholesterol, TG, LDL, and HDL, 5-6 years post-partum. The total
enrollment was 106, with 58 prior GDM (cases) and 48 age matched comparison subjects
recruited 5-6 years postpartum from the Diabetes in Pregnancy Screening Program in
Providence, Rhode Island Women and Infant's Hospital. GDM exposure was defined as
confirmed diagnosis of GDM via 1-hr glucose tolerance and 3-hr GTT tests performed during
24-28 weeks of gestation. Mothers who had GDM received nutritional counseling, and were
closely monitored for blood glucose levels throughout the pregnancy; insulin therapy was
recommended in the case of high glucose levels. The authors assessed fasting lipid levels via
fasting morning blood samples during a median follow-up of 5-6 years after pregnancy. The
authors found the following results for maternal lipids in GDM vs. non-GDM mothers: In
mg/dL; slightly higher mean TC (189.87 vs. 165.89, p=0.005); slightly higher mean TG (131.08
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vs. 85.03, p=0.02); slightly higher mean LDL (121.81 vs. 105.18, p=0.01); and slightly higher
mean HDL: (49.11 vs. 44.86, NS, p-value not provided). In Meyer-Seifer et al.’s study, the
utilization of GDM diagnosis via past medical records to determine current GDM status raises
the possibility of misclassification of exposure, possibly biasing the results towards the null.
Also, in this study, GDM subjects were closely followed and advised for their dietary intake
while comparison non-GDM subjects were not, challenging the interpretation of comparisons
between the groups.
3.2. Epidemiology of GDM and Cord Blood Lipid Relationship
Few studies have examined the impact of GDM on cord blood lipids (24, 26, 27, 31).
Marseille-Tremblay et al (2008), Sobki et al. (2004), and Abou Ghalia et al. (2003), and Couch
et al. (1998) have examined this association with mixed findings for total cholesterol,
triglycerides, and LDL cord blood lipids. As previously noted, blood lipid concentrations are
expressed either in mmol/L or mg/dL with a conversion factor of 38.67 for serum total
cholesterol, LDL, and HDL (1 mmol=38.67 mg/dL), while serum triglycerides have a conversion
factor of 88.57 (1 mmol=88.57 mg/dL) (29, 30).

In their small prospective, hospital-based cohort study, Marseille-Tremblay et al. (24)
assessed newborn lipid outcomes via cord blood samples collected at delivery. The authors found
the following means±standard errors for cord blood lipids in GDM vs. non-GDM mothers, in
mg/dL: slightly lower TC: 69.61±23.20 vs. 69.99±7.73, slightly lower TG: 55.80±7.09 vs.
62.0±8.86, slightly lower LDL: 29.0±2.71 vs.30.16±4.25, slightly higher HDL: 34.03±6.19 vs.
26.30±4.64 (all comparisons were non-significant, p-values not provided). Once again, observed
differences in this small study were small and not statistically significant. Also, the use of GDM
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women who were exclusively treated with insulin may suggest a less representative sample of
women with exceptionally altered metabolic profiles compared to the majority of women with
GDM (32).
Sobki et.al (26) conducted a hospital-based cohort study in Saudi Arabia in 2004, where
they sought to examine the effect of gestational diabetes on biomarkers of oxidative stress and
cardiovascular risk in cord blood samples obtained at delivery. The authors found the resulting
following means for cord blood lipids in GDM-diet-treated/GDM-insulin-treated vs. non-GDM
women: TC: 1.51/1.51 vs. 2.03 (non-significant, no p-value provided); TG: 0.40/0.31 vs. 0.64
(p<0.05), LDL: 0.79/0.86 vs. 1.97 (p<0.05); and HDL: 0.58/0.68 vs. 0.72 (p<0.05). Overall, they
found that cord blood lipids were significantly, albeit slightly, lower in GDM women compared
to non-GDM women. Proposed rationale for the lower levels observed in cord blood lipids of
GDM women involves the hypothesis that neonatal plasma lipoprotein levels are lower than in
adults, and that neonates of diabetic women are subject to a higher rate of oxidative metabolism
as a result of maternal hyperlipidemia and hyperglycemia. Also, all GDM women were either
diet or insulin-treated, compared to non-GDM with no treatment, which may have lowered or
altered their cord blood lipids, biasing their results towards the null.
Abou Ghalia et al. (31) conducted a prospective study of 77 pregnant women who were
classified according to their GDM status (i.e., GDM, insulin-dependent DM, non-insulin
dependent DM, or non-gestational DM). The authors assessed GDM status through verification
of family/obstetric medical records. LDL: HDL ratio was assessed via a 10 mL cord blood
sample obtained immediately after delivery. The authors found the following mean±standard
deviations in cord blood samples from GDM vs. non-GDM (healthy) mothers: in mg/dL; slightly
higher TC: 73.47±24.36 vs. 65.74±15.47 (NS, no p-value provided), slightly lower TG:
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33.66±16.83 vs. 40.74 ±15.06 (NS, no p-value provided) slightly higher HDL: 34.80±13.92 vs.
29.0±11.60 (NS, no p-value provided) and slightly higher LDL: 31.32±18.17 vs. 23.59±10.05
(NS, no p-value provided). None of these findings reached statistical significance. The inclusion
of women with non-gestational diabetes for comparison with control mothers in this study limits
speculation upon the specific effects that GDM may have on cord blood lipid profiles. Lastly by
only focusing on the LDL: HDL ratio, Abou Ghalia et al. fail to investigate the effect of GDM on
other important components of blood lipids like triglycerides and total cholesterol levels in cord
blood.
In Couch (27) et al.’s study, the authors assessed GDM exposure by administering a 1hr50g glucose tolerance test, followed by a 3hr GTT, at 24-28 weeks gestation to confirm GDM
diagnosis. Cord blood lipid outcomes were assessed via blood samples collected at delivery. The
authors found the following means±standard deviations of maternal lipids in GDM vs. non-GDM
mothers (in mg/dL): TC: 53.58±14.01 vs. 54.82±13.80 (NS, no p-value provided), TG:
36.68±12.31 vs. 43.71±14.80 (NS, no p-value provided); LDL: 32.29±12.09 vs. 32.20±13.84
(NS, no p-value provided); and HDL: 21.30±5.42 vs. 22.07±7.09 (NS, no p-value provided).
None of these results were statistically significant. Although Couch et al. sought to examine the
direct effect of GDM on maternal and cord blood lipid outcomes, GDM women were dietcontrolled, while controls were not, and they consequently gained significantly less weight than
controls which could have altered their lipid profile, biasing the results towards the null.
3.3. Summary
Gestational diabetes, a hyperglycemic manifestation of metabolic syndrome during
pregnancy, is estimated to affect 18% of pregnancies and is postulated to affect the
cardiovascular health of mother and child long after gestation. Metabolic syndrome is currently
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estimated to affect close to half of the United States population (4) and is known to increase an
individual’s future risk for cardiovascular disorders (5). Hyperlipidemia, obesity, and insulin
resistance, which are increasingly prevalent metabolic risk factors, are responsible for the
development of metabolic syndrome. Current knowledge about the effect of gestational diabetes
upon maternal and cord blood lipids is limited. Among those that have been conducted, small
sample size, and issues with determination of GDM status, differences in management of GDM
during pregnancy, and timing and measurement of lipid levels have resulted in ambiguity
regarding this association. More studies are needed to elucidate this association, especially
studies with sufficient sample size, and assessment of lipids both during gestation and after
delivery. We propose to use prospective data from Baystate Medical Center’s GDM and Lipid
Metabolism study to examine the association between gestational diabetes and maternal blood
lipids and cord blood lipids both during and after pregnancy.
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CHAPTER 4
HYPOTHESIS AND AIMS
Specific Aim #1: We propose to examine the association between gestational diabetes
mellitus (GDM) and maternal blood and cord lipids, namely, total cholesterol,
triglycerides (TG), high density lipoproteins (HDL), and LDL (low density lipoproteins),
in a prospective cohort of women from the Baystate Maternal and Fetal Medicine unit.
a. Hypothesis 1: Compared to women without GDM, women with GDM have
elevated levels of total cholesterol, TG, LDL, and lower levels of HDL, both
during pregnancy and postpartum.
b. Hypothesis 2: Compared to the cord blood of women without GDM, the cord
blood of women with GDM has elevated levels of total cholesterol, TG, LDL, and
lower levels of HDL.
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CHAPTER 5
METHODS
5.1. Source Data
Our study evaluated the association between gestational diabetes mellitus (GDM) and
lipid metabolism in pregnant mothers (maternal blood lipids) and their infants (cord blood lipids)
using existing data from a prospective cohort study conducted in Springfield Massachusetts
between 2007 and 2009 amongst women obtaining services from Baystate Medical Center’s
Wesson Women and Infant’s Unit. Baystate Medical Center is a tertiary care hospital and is the
largest of four Baystate Health hospitals in the Western Massachusetts region.

Subjects for

this study were women that came in to the Wesson Women’s Baystate Reference Laboratory
Satellite office to receive a 3-hour glucose tolerance test (GTT), a procedure used to test for
gestational diabetes. The GTT was performed among pregnant patients at around 24-28 weeks of
gestation. Eligible women were those who had failed a preliminary fasting, 50 g, glucose test (1
hr GTT) and consequently were scheduled for the follow-up 100 g, 3-hr GTT to confirm their
GDM status (Table 1). A single staff member from the Maternal and Fetal Medicine visited the
Wesson Lab regularly to interview and then recruit women for the study. Information on
ethnicity (Table 3) and self-reported family member history of elevated lipids, diabetes,
myocardial infarction, and stroke were collected at this time (Table 3).
In accordance with the study protocol, maternal lipids were first assessed around 24-28
weeks gestational age using the same blood samples utilized for the GDM screen at baseline,
allowing for simultaneous assessment of exposure and outcome. With knowledge of GDM
status, postpartum lipids were then obtained prospectively at 6-8 weeks post-delivery to examine
the prolonged effects of GDM on maternal lipids (Figure 1). Cord blood samples were obtained
from the women at the time of birth.
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While 398 women were initially approached for our study, 289 were excluded because
they either refused, were ineligible, or terminated due to pregnancy complications. Patients were
asked to identify if they fulfilled any exclusionary criteria and signed an informed consent form
approved by Baystate Medical Center’s Institutional Review Boards before they provided any
personal/interview information. Study exclusions included: a history of diagnosis of diabetes,
hypertension, heart disease, or chronic renal disease, prior history of lipid disorder or metabolic
syndrome, current medications thought to adversely influence glucose tolerance, non-singleton
pregnancy, < 16 or over 40 years of age, and the intention to deliver outside Baystate (Table 3).
Additional caveats for termination after enrollment included having a GCT (fasting plasma
glucose) ≥150 followed by a normal 3 hour GTT, due to the suggested possibility of an
underlying insulin resistance in women that are diagnosed as non-GDM (healthy women), being
unable to complete the 3-hr GTT, phlebotomy/lab errors, and withdrawal from the study prior to
obtaining GTT results. Women were also excluded if they withdrew from the study due to
miscarriage, subsequent pregnancy, or loss-to-follow-up (Table 1). Also, exclusions were made
if a recruitment arm of the study, GDM or non-GDM was fulfilled.
5.2.

Exposure Assessment
The exposure of interest is gestational diabetes mellitus, which we dichotomized into two

groups of GDM (exposed) and non-GDM (unexposed) (Table 2). GDM is routinely diagnosed in
a two-step process, first by patient history, clinical risk factors, or with a 50-g, 1 hour loading
test at 24-28 weeks of gestation, and second by resulting values from a 100-g, 3-hr glucose
tolerance test for diagnosis (33, 34). The “GDM exposed” group were defined using Carpenter
and Coustan criteria (35, 36) as having elevated glucose values for two or three samples over the
3 hour (total of 3 samples) GTT, while the non-GDM, “unexposed” (healthy) group were
identified as those with one or no abnormal glucose values over the 3 hour GTT. Unexposed
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women were required to lack prior diagnosis of diabetes before pregnancy. Carpenter and
Coustan criteria determines GDM status via the following cut-off points: a fasting value of 95
mg/dL, 1-hour value of 180 mg/dL, 2 hour value of 155 mg/dL, and 3 hour value of 140 mg/dL
(37). All blood glucose assessments were performed at the Wesson Women’s Baystate Reference
Laboratory.
5.3.

Validity of Exposure Assessment
The 3 hour 100g test is recommended by the ADA and is based on O’Sullivan’s hallmark

studies in the 70’s (33, 34) to diagnose women with GDM. More recently, the internationally
sponsored HAPO study (38) used the 3 hr-GTT to evaluate if elevated glucose values were
associated with greater odds of adverse pregnancy outcomes, such as hypertension (39). Using
this method, the researchers observed a consistently increased risk for hypertensive disorders for
elevated values at fasting (OR: 1.21; 95% CI: 1.13-1.29), 1-hour glucose (OR: 1.28; 95% CI:
1.20-1.37), and 2-hour glucose (OR: 1.28; 95% CI: 1.20-1.37). The ACOG 2001 Practice
Bulletin for Gestational Diabetes acknowledges that the optimum threshold for diagnosing GDM
is elusive and hence more than one threshold is acceptable (36). The American Diabetes
Association ascribes approximately 90% sensitivity to the 130 mg/dL cutoff mark, and 80%
sensitivity to the cutoff mark of 140 mg/dL (last abnormal value of 3 hr GTT) (40). Although
both values are acceptable, a more conservative threshold is ideal to avoid false positive
diagnoses of GDM.
5.4.

Outcome Assessment
Our outcomes of interest were maternal and cord blood levels of four variables: total

cholesterol, triglycerides, HDL, and LDL cholesterol. Women’s total cholesterol, HDL, LDL,
and triglyceride lipid levels were collected as fasting and 3 hour GTT-congruent measurements
both at 24-28 weeks of gestation (baseline), and then at 6-8 weeks postpartum (Table 4), while
19

cord blood samples were collected immediately after birth. Fasting glucose, 3 hour OGTT, and
cord blood levels of all four outcome variables were evaluated continuously (Table 5). National
guidelines were used to classify maternal lipids into binary high and low categories.
Hyperlipidemia was diagnosed using national standards from the National Institute of
Health’s Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Adult
Treatment Panel III (ATP III) (41). Hyperlipidemia is defined as the presence of excess blood
lipids based on nationally-determined guidelines (41). The recommended level for total
cholesterol is <200 mg/dL, for LDL is <100 mg/dL, for triglycerides is <200 mg/dL, and for
HDL is between 40 mg/dL and 60 mg/dL (41).
5.5.

Validity of Outcome Assessment
Our use of a fasting and then non-fasting sample while the patients came in for their

regular visit is deemed one of the most acceptable and feasible ways to screen for lipid disorders
(35). A study done by Bansal et al. in 2007 (42) evaluated the association of fasting and nonfasting triglyceride levels at enrollment with incident cardiovascular events over a median
follow-up of 11.4 years in women. The authors found that triglyceride levels measured 2 to 4
hours post-prandially had the strongest association with cardiovascular events (fully adjusted
hazard ratio [95% confidence interval] for highest vs. lowest tertiles of levels, 4.48 [1.98-10.15]
[P <.001 for trend]), and this association progressively decreased with longer periods of fasting.
This finding emphasizes the importance of non-fasting samples in reflecting the true effect of
lipids resulting from meal consumption upon disease risk and incidence. Lastly, we expect the
coefficient of our lab measurement to be valid and within the accepted 30% range because it is
certified according to the government-monitored Clinical Laboratory Improvement Amendments
(CLIA) standard.
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5.6.

Covariate Assessment
Data for covariates were collected via self-report through a “Lipid Metabolism and GDM

Study: Patient Screening and Interview Form” administered at the time of recruitment.
Specifically, date of birth, age at enrollment, expected date of delivery, gestational age at time of
sample collection, BMI, race, medications, history of thyroid disease, infertility, and other
serious medical conditions were collected via mostly multiple choice questions in the interview
form (Table 3). Medical record abstraction was used to determine whether the women had
experienced GDM in previous pregnancies. Family history, by closeness of relative, was also
collected for elevated lipids, diabetes, myocardial infarction, and stroke (Table 3). Previous
studies have shown that race (43), maternal BMI (44), and family history (39) are strong risk
factors for future cardiometabolic disorders in mother and child, of which GDM and abnormal
maternal and cord blood lipids are a proxy.
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CHAPTER 6
STATISTICAL ANALYSIS
In preliminary analysis, descriptive statistics were computed to describe the
characteristics of the study cohort. In the main analyses, normal theory linear regression models
were used for the continuous outcomes (TC, TG, LDL, and HDL lipid values) and logistic
regression approaches were used in analyses of dichotomized measures of TC, TG, LDL, and
HDL. Single predictor models were fit to obtain model free estimates of associations with lipid
levels. Multiple predictor models were fit to estimate associations of GDM with outcome,
controlling for age, BMI, and gestational age, either at recruitment or delivery. My approach to
model fitting involved a backward elimination process where all covariates of potential interest
were included and sequentially removed by using partial F-tests for linear regression and
likelihood ratio tests for logistic regression, with a Type I error of <0.05.

6.1.

Data Analysis Plan for Maternal Blood Lipids Outcome

6.1.1. Univariate Analysis
Hypothesis 1: Compared to women without GDM, women with GDM have elevated levels of
total cholesterol, TG, LDL, and lower levels of HDL, both during pregnancy and
postpartum.
In univariate analysis, descriptive statistics of the study variables were computed
separately for both GDM and non-GDM mothers. The number and characteristics of the study
population that were lost during follow-up are presented in Table 1 while the percent distribution
of GDM/non-GDM mothers is presented in Table 2. The distributions of covariates by GDM
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status are presented in Table 3. For continuous variables, means and standard deviations are
presented, while for discrete variables frequencies and relative frequencies are shown.
6.1.2. Bivariate Analysis
Covariates were cross-tabulated with total cholesterol (TotChol), triglycerides (TG),
HDL, and LDL for maternal blood lipids (Table 4), to evaluate potential confounders. P-values
from Chi-square, ANOVA, or Student t-tests which reflect the differences in distributions are
presented for all of the covariates. We used directed acyclic graphs (DAGs) to examine
relationships between the covariates and the exposure and outcome. Unadjusted linear (for
continuous variables) and logistic (for categorical variables) regression models were used to
evaluate the effect of covariates on the association between GDM and maternal lipids (Table 6,
7a, 7b, and Table 8).
6.1.3. Multivariable Analysis
We modeled the relationship between GDM status and continuous maternal blood lipid
levels first using multivariable linear regression to calculate beta coefficients, standard errors,
and p-values, for both fasting , 3-hr GTT values, at baseline and 6-8 weeks postpartum (Table 6).
We evaluated this relationship by treating maternal blood lipids as a dichotomous variable and
evaluating the odds of observing high maternal blood lipid levels among exposed vs. unexposed
using multivariable logistic regression to calculate odds ratios (ORs) and 95% confidence
intervals (Table 8). Three multivariable logistic regression models were run for fasting and 3hr
GTT maternal lipids at baseline and for fasting at 6-8 weeks postpartum (Table 8).
Confounders were evaluated by running all models with and without their presence. Any
covariate that changes the estimate for GDM exposure by 10% or greater was retained in the
model as a confounder.
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6.2.
Data Analysis Plan for Cord Blood Lipids Outcome
Hypothesis 2: Compared to the cord blood of women without GDM, the cord blood of women
with GDM has elevated levels of total cholesterol, TG, LDL, and lower levels of HDL.
6.2.1. Univariate Analysis
The percent distribution of GDM/non-GDM (Table 1) and the distribution of cord blood
cholesterol (TotChol), triglycerides (TG), HDL, and LDL are presented as well (Table 5).
6.2.2. Bivariate Analysis
Covariates were cross-tabulated with GDM exposure (Table 3) and cord blood lipid
outcomes (Table 5) to evaluate potential confounders. P-values from Chi-square, ANOVA, or
Student t-tests reflect the differences in distributions for all of the covariates. We used directed
acyclic graphs (DAGs) to examine relationships between the covariates and the exposure and
outcome. Unadjusted linear models were also used to evaluate the effect of covariates on the
association between GDM and cord blood lipids (Table 6).
6.2.3. Multivariable Analysis
We modeled the relationship between GDM status and continuous variable lipid levels
first using multivariable linear regression to calculate beta coefficients, standard error, and pvalues (Table 6). Insufficient low cord blood lipid levels prevented us from evaluating the odds
of observing high lipid cord blood lipid levels among exposed vs. unexposed using multivariable
logistic regression to calculate ORs and 95% confidence intervals (Table 8).
Confounders were evaluated by running all models with and without their presence. Any
covariate that changes the estimate for GDM exposure by 10% or greater was retained in the
model as a confounder.
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CHAPTER 7
RESULTS
7.1.

Analysis Cohort
A total of 109 women were initially enrolled in our study, with 61 non-GDM and 48

GDM mothers. Of the 109 pregnant women originally recruited for this study, 2 women without
GDM and 1 woman with GDM withdrew from the study prior to delivery (n=3), resulting in a
final cohort of 106 women with information available through delivery (Table 1 and Table 2).
An additional 7 women withdrew after delivery, of whom 6 were without GDM. Only two GDM
women were excluded due to miscarriage and subsequent pregnancy, respectively, and 54.1% of
non-GDM mothers vs. 41.7% of GDM mothers were lost due to follow-up. Slightly more than
half of the women in our study (55.7%) did not have gestational diabetes (Table 2). The
availability of blood lipid values varied throughout the course of this study as there was
significant loss-to-follow-up postpartum (Table 1).
Due to the logistical challenges of conducting a prospective pregnancy cohort, there was
a substantial amount of missing data due to missed clinic visits and/or dropout in our cohort. Of
the 106 in the analysis cohort, complete data was successfully obtained from 24 women (22.6%),
which included having complete lipid values for maternal baseline fasting, maternal baseline+3rd
hour GTT, maternal postpartum, and cord blood. Eighty-four (79.2%) participants had at least
one lipid outcome missing over the course of the study. Of the 24 women with complete
information, 14 were GDM women, and 10 were non-GDM women. This slight difference in
participant retention by GDM status represents a potential bias for our results. Therefore, we
sought to address the possibility of informative censoring by comparing the crude and adjusted
association of GDM with lipids by patterns of missingness in 3 ways: in the analysis cohort as a
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whole (n=106), in the women with at least one missing value (n=84), and in the women with
complete information (n=24). These results are further explained as a secondary component of
the linear regression analyses (Table 7a and 7b).
Table 3 presents the distribution of potential physiologically meaningful covariates
according to GDM status. The mean age for mothers in this population was 30.48 years
(SD±5.28), with a non-significant association between age category and GDM status (p=0.13).
Mothers with gestational diabetes were slightly older than those without gestational diabetes
(31.6 vs. 29.6 yrs., p=0.05), and were also recruited for the study at an earlier gestational age (27
vs. 29 weeks, p=0.02). Gestational age at delivery was similar in the two groups (38.5 vs. 38.9,
p=0.27). Mothers with GDM had a higher mean BMI of 33.72 (SD±1.10) compared to a mean
BMI of 30.29 (SD±.84) for mothers without GDM (p=0.01). Neither race (p=0.73) nor history of
thyroid disease (p=0.82) were associated with GDM status. Six women reported past experiences
of infertility, of whom 5 were GDM mothers compared with 1 without GDM (p=0.05).
Similarly, GDM and non-GDM mothers reported having similar backgrounds for family history
of metabolic disease, but a greater proportion of non-GDM mothers reported having no family
history (p=0.09).
7.2.

Distribution of Lipids by Covariates
The distribution of maternal total cholesterol (TotChol), triglycerides (TG), low-density

lipoproteins (LDL), and high-density lipoproteins (HDL) by covariates at both the baseline and
postpartum visits are presented in Tables 4a-4c. Age was not associated with higher lipids for the
fasting and 3rd hour of the glucose tolerance test (GTT) at the baseline visit (Tables 4a and 4b).
Age, however, was associated with higher TotChol (p=0.02) and LDL (p=0.04) in the 6-8 week
maternal postpartum lipid sample (Table 4c). BMI was associated with modestly higher TG as
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well as modestly lower TotChol, LDL, and HDL at all timepoints. At the fasting antenatal visit,
there was a significant association between overweight and obese BMI categories and lower
LDL (p=0.06) and HDL values (p=0.01), while at the 3rd hour of the antenatal visit there was a
significant association between overweight and obese BMI categories and higher TG (p=0.02)
and lower HDL values (p=0.02) (Table 4a). Higher postpartum HDL was associated with lower
BMI (p<0.001). Though few in our study population, mothers of Asian and other races were
shown to have higher fasting (p=0.05) and 3hr triglyceride levels (p=0.01) at the baseline visit;
there was no significant association between race and lipid values at the postpartum visit.
Infertility and family history were not associated with maternal lipid values at any of the three
possible timepoints.
The distribution of the four blood lipid outcomes by covariates as measured in cord blood
samples obtained at delivery are presented in Table 5. Continuous and categorical age were not
significantly associated with the lipid values, although a significant 0.50 decrease in HDL was
observed for a unit increase in continuous BMI (p=0.03). Race was not associated with cord
blood lipid values. Infertility was observed to be associated with higher TG levels (p=0.003),
while family history of metabolic disease was significantly associated with higher LDL levels
(p=0.03).
7.3.

Multivariable Linear and Logistic Regression
Tables 6a-6d show both crude and adjusted group mean associations of blood lipids for

women with GDM compared to women without GDM. At the fasting antenatal visit (Table 6a:
Model 1), unadjusted linear regressions of TC, TG, LDL, and HDL levels, comparing GDM to
non-GDM women, resulted in an overall lower lipid values for GDM women with total
cholesterol values that were significantly lower by 27.74 mg/dL (217.35 mg/dL vs. 245.08

27

mg/dL, p=0.002) and LDL values that were lower by 22.1 mg/dL (115.15 mg/dL vs. 137.25
mg/dL, p=0.003). Adjusted group means for age, BMI, and gestational age at recruitment
produced less pronounced lower values for GDM women compared to non-GDM women for
TC (220.52 mg/dL vs. 242.53, p=0.015) and LDL (117.87 vs. 134.81 mg/dL, p=0.027).
Similarly, at the 3rd hour of the antenatal visit (Table 6b: Model 2), crude group means of
TC, TG, LDL, and HDL lipid values, comparing GDM to non-GDM women, resulted in overall
lower lipid values for GDM women with a significant total cholesterol values lower in GDM
women by 24.29 mg/dL (209.59 vs. 233.88 mg/dL, p=0.003) LDL values by 20.17 mg/dL
(111.85 vs. 132.02 mg/dL, -p=0.004), and HDL values by 6.62 mg/dL (61.13 vs. 61.46 mg/dL,
p=0.014). Group means adjusted for age, BMI, and gestational age at recruitment produced less
pronounced values of TC in GDM women compared to non-GDM women that were lower by
20.11 mg/dL (211.81 vs. 231.91 mg/dL, p=0.018), LDL levels lower by 16.57 mg/dL (113.65 vs.
130.22 mg/dL, p=0.024), and HDL levels lower by 5.87 mg/dL (61.46 vs. 67.33 mg/dL,
p=0.042).
Crude and adjusted group means for postpartum maternal lipids (Table 6c: Model 3)
produced significantly higher values of TG, in GDM women compared to non-GDM women, by
37.43 mg/dL (126.88 vs. 89.45 mg/dL, p=0.042) and lower HDL values in GDM compared to
non-GDM women by 10.86 mg/dL 49.79 vs. 60.65 mg/dL, p=0.007); however, the magnitude of
TG and HDL difference was minimized and became insignificant after adjusting for age, BMI,
and gestational age at time of delivery in weeks (p=0.58, and, p=0.21, respectively).
Crude group means for cord blood lipids (Table 6d: Model 4) at delivery, comparing
GDM to non-GDM women, resulted in a significantly higher TG values for GDM women by
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13.23 mg/dL (41.80 vs. 28.57 mg/dL, p=0.043), higher LDL values by 5.53 mg/dL (29.92 vs.
24.39 mg/dL, p=0.047), and lower HDL values by 5.28 mg/dL (24.76 vs. 30.04 mg/dL,
p=0.057). Group means adjusted for age, BMI, and gestational age at time of delivery in weeks
(Model 4: Adjusteda) showed slightly higher TG values (p=0.05) and LDL values (p=0.03) for
GDM women compared to non-GDM women. We were also interested in examining whether
maternal fasting antenatal lipids had an intermediary effect upon cord blood lipids. However,
adding the maternal fasting antenatal lipid fraction as a covariate to the adjusted cord blood
lipids model (Model 4: Adjustedb) did not significantly affect the regression coefficients.
As there was substantial missing data, in order to evaluate the possible influence of
dropout as a bias, secondary crude (Table 7a) and adjusted (Table 7b) analyses were performed
comparing those with complete data and those with missing data. Overall, no significant
differences were observed for these analyses, though the regression coefficients for women with
missing data (n=82) were more comparable to those of the whole cohort (N=106) than those for
women who had complete data from all time points (n=24).
Crude and adjusted odds ratios for the odds of elevated lipid levels by GDM status are
shown in Tables 8a-8c. In models of high fasting antenatal total cholesterol levels, compared to
women without GDM, we observed 60% lower odds for high lipid levels in mothers with GDM
(OR: 0.375, 95%CI: 0.153-0.922; p-value: 0.033) and ~66% lower odds for high lipid levels in
maternal 3hr antenatal high total cholesterol levels for mothers with GDM (OR: 0.34, 95%CI:
0.13-0.87; p-value: 0.024). The remaining OR estimates were not statistically significant, both
unadjusted as well as those adjusted for maternal age and BMI.

29

CHAPTER 8
DISCUSSION
In our study, we observed overall lower maternal blood lipids at 24-28 weeks gestation
and higher cord blood lipids for those women with gestational diabetes; no association was
observed between GDM status and maternal blood lipids postpartum. Differences in lipid levels
between GDM and non-GDM mothers were small, of magnitudes comparable to previous
studies, and of questionable clinical importance. Our findings are partially inconsistent with
previous observations of higher total cholesterol, triglycerides, low-density lipoproteins, and
lower high-density lipoproteins for maternal blood lipids (21, 22, 23, 24, 25, 26, 27, 28), and
conflicting associations for cord blood lipids (24, 26, 27, 31).
Whereas we observed nonsignificantly higher postpartum TG levels in GDM women
compared to non-GDM women (115.99 vs. 106.07 mg/dL, p=0.58) and lower HDL levels (52.11
vs. 56.70 mg/dL, p=0.22), Lauenborg et al. (8) found slightly higher TG: 115.14 vs. 88.57
mg/dL, p<0.0005, and slightly lower HDL: 54.14 vs. 58.0 mg/dL, p<0.0005 in prior GDM
women compared to non-GDM women. Although Lauenborg et al.’s findings were deemed
statistically significant; the clinical significance of their small magnitude findings is
questionable. In previous studies maternal lipids were also sampled across various timepoints,
ranging from during delivery to several years postpartum, which might reflect changes in the
maternal lipid profile over time. Our study used Carpenter and Coustan criteria, diagnosed
women for GDM with the OGTT at 24-28 weeks gestation, and obtained lipids between 6 weeks
to 6 months postpartum, a much shorter follow-up period. Assuming women are more closely
monitored and managed for hyperglycemia and dyslipidemia during pregnancy, and that the
negative consequences of GDM worsen over time, it is possible that by assessing maternal lipids
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during and soon after pregnancy the negative effects of GDM were underestimated in our study,
biasing our results towards the null.
Consistent with our findings, Abou Ghalia et. al found lipid means±standard deviations
with higher TC: 168±55.80 vs. 150.57±35.43 mg/dL; slightly higher HDL: 34.80±13.92 vs.
29.0±11.60 mg/dL, and slightly higher LDL: 31.32±18.17 vs. 23.59±10.05 mg/dL in cord blood
samples of GDM women vs. non-GDM women. In contrast, Sobki et. al (27) and MarseilleTremblay et al. (24) found overall lower cord blood lipid levels in GDM women. In both Sobki
et. al and Marseille-Tremblay et al.’s studies, all the GDM women were either diet or insulin
treated, whereas in Abou Ghalia et. al’s study GDM women were combined with women with
non-gestational (pre-pregnancy) diabetes for comparison with non-GDM women. Thus, some of
the women in Abou Ghalia et al’s study may have had an underlying risk for dyslipidemia
because their first incidence of diabetes was prior to pregnancy, possibly biasing their results
away from the null. Although differences in cord blood lipid levels in previous studies as well as
our present study may have reached statistical significance, clinical significance is likely minor.
Our study had the strengths of administering OGTTs during the course of the study and
access to lipid profiles from fasting and 3-hr blood samples obtained both during and after
pregnancy. However, the incompatibility of our results with previous studies and the uncertainty
about their clinical significance warrants an examination of possible limitations. We suspect that
while multiple factors are at play, limited statistical power, methodology and timing of GDM
classification, timing of lipid assessment, selection bias via non-random dropout, unmeasured
confounders, and sampling variability may account for the differences between our and previous
studies’ results. One should consider that our result of nonsignificant lower lipids in women with
GDM could represent a true association.
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CHAPTER 9
STUDY LIMITATIONS

9.1. Nondifferential Misclassification
9.1.1. Nondifferential Misclassification of Exposure (Gestational Diabetes Mellitus)
Pregnant women who failed the initial GCT (glucose challenge test) were scheduled for
the follow-up 3-hr GTT (glucose tolerance test), in which two or more samples of elevated
glucose levels confirmed gestational diabetes mellitus (GDM) status. GDM status was
determined based on results of these tests at 24-28 weeks gestation. GDM status may be
misclassified due to error (e.g., due to laboratory error, unaccounted circadian variation, etc.), or
because of change in status between the time it was determined and later in pregnancy, or the
type of diagnostic criteria used. In the Lauenborg study, for instance, GDM assessment was
attained by using risk factor based Dutch diagnostic criteria instead of the more widely used
OGTT and Carpenter and Coustan criteria, possibly suggesting that pre-diabetic non-GDM may
have been counted as GDM in other studies, biasing their results towards the null. However, we
expect that this misclassification of GDM was minimized in our study because of the use OGTTs
that were analyzed at the Wesson Women’s Baystate Reference Laboratory, a CLIA (Clinical
Laboratory Improvement Amendments) certified facility. This centralized processing of the
samples greatly reduces variability in laboratory processes, which minimizes the likelihood and
magnitude of this potential bias. Although the chances of GDM status changing after 7 months of
pregnancy may be small, there is a possibility that a woman could develop GDM in the last stage
of pregnancy. This misclassification of exposure would have biased our results toward the null
because women who go on to develop GDM late in their pregnancy would be considered as nonGDM throughout the study. Given that we are unaware if and when women in our study were
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monitored and managed for their GDM we cannot be sure of the extent of this potential
misclassification.
9.1.2. Nondifferential Misclassification of Outcome I – Maternal Lipids
Variability in how the samples were collected, transferred, and analyzed could
have resulted in lab error with measurement of maternal lipids values. This laboratory error
could have therefore lead to misclassification of the outcome. Because laboratory personnel were
not aware of GDM status for biospecimens used to determine lipid levels, we expect any such
misclassification to be non-differential and therefore would have biased our results towards the
null. However, we expect that this misclassification of maternal lipid levels was minimized
because all lipid assessments were performed at the Wesson Women’s Baystate Reference
Laboratory, a CLIA certified facility. This centralized processing of the samples greatly reduces
variability in laboratory processes, which minimizes the likelihood and magnitude of this
potential bias.
9.1.3. Nondifferential Misclassification of Outcome II- Cord Blood Lipids
Cord blood lipids were obtained from mothers shortly after delivery, via a 5 cc sample of
blood. Given the immediate and precise collection of blood after delivery, misclassification of
the outcome is unlikely. However, differences in how the samples were collected, transferred,
and analyzed could lead to lab error and variability in assessing maternal lipids values. This
laboratory error could therefore have led to nondifferential misclassification of this outcome,
which may bias our results towards the null. However, we expect that this misclassification of
high and low cord blood lipids was minimized because all lipid assessments were performed at
the Wesson Women’s Baystate Reference Laboratory, a CLIA (Clinical Laboratory
Improvement Amendments) certified facility. This centralized processing of the samples greatly
reduces the likelihood and magnitude of this potential bias.
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9.2.

Selection Bias
Due to the prospective nature of this study, likelihood of selection bias related to

recruitment is minimal, because exposure status (GDM) was determined before lipid levels were
analyzed. However, selection bias may have occurred due to loss-to-follow-up in the pregnancy
cohort, especially postpartum. The new stresses of motherhood can deter women from coming in
for their postpartum lipid assessment, which could have either biased our results towards or away
from the null, depending on the GDM status of those women who were lost. For example, if
women lost to follow-up were more likely to have GDM and with higher levels of blood lipids, a
selection bias would have occurred that would cause the results of this study to be biased towards
the null. Also, we observed an earlier time of enrollment (i.e., lower gestational age at
recruitment) among GDM mothers compared to non-GDM mothers. Perhaps, this slightly earlier
recruitment and reduced loss-to-follow-up of GDM mothers reflects more intensive management
of women with GDM, with the limitation of not knowing whether GDM mothers were managed
for glucose or lipids during pregnancy. On the other hand, if women who did not have GDM and
had elevated lipids were more likely to be lost to follow-up, perhaps due to the presumption of
being healthy, this selection bias would have biased our results away from the null. In our study,
women lost to follow-up were similar to those with complete (including postpartum) information
and therefore any selection bias that occurred in this cohort due to loss to follow-up appears to be
minimal.
9.3.

Differential Misclassification
Women in this study were followed from the time of GDM ascertainment (24-28 weeks)

until about 2 months after delivery. Although within 2 months after delivery was the ideal
follow-up period for postpartum lipids, many women were recontacted up to 6-8 months after
delivery. Thus, the postpartum lipid profiles of mothers are likely to have varied by their time of
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follow-up. The laboratory technicians who analyzed these women’s lipid profiles were blinded to
the women’s GDM status, so any differential treatment of the blood samples is unlikely. It is
equally unlikely that the women’s lipid levels were inaccurately or differentially assessed, as
long as the same tests/methods and personnel were used to analyze all the samples. If different
laboratory lipid assessment methods were utilized by different technicians across the samples,
our results could potentially be biased in an unknown direction, depending on the nature of the
method and technician. However, we expect minimal bias to have occurred due to the blinding of
GDM status, standardized, CLIA-certified laboratory procedures, and adherence to lab protocol.
9.4.

Confounding
We evaluated measured confounders by controlling for them in our analysis, using

multivariable linear regression and stratification. Three measured confounders in our study were
gestational age, maternal BMI, and gestational age at recruitment, and gestational age at
delivery.
A number of additional potential confounders would have been beneficial to consider in
our study. Information was not collected on whether the GDM mother was primiparous or had
experienced GDM in prior pregnancies, whether the mother was managed for GDM or
dyslipidemia during the study, the mothers’ change in BMI over the course of the study,
(clinical) history of familial hypercholesterolemia, and maternal diet both before and throughout
the course of pregnancy.
It is useful to know whether this was the first GDM pregnancy experienced by the mother
because it has been proven that prior experience of GDM is predictive of future GDM
pregnancies and long-term cardiovascular risk (45). For instance, if most of our study
participants had experienced GDM in a previous pregnancy, we are likely to have overestimated
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the independent influence of GDM on lipids, as they are likely to be other underlying risk factors
for dyslipidemia.
Treatment for GDM or dyslipidemia during pregnancy is an important covariate for
which we lacked information. By not knowing which women may have been diet-controlled or
medicated for their GDM we are prone to either under or overestimating the association between
GDM and maternal and cord blood lipids. Also, the fact that maternal serum glucose values only
provide an instantaneous snapshot of the mother’s glucose control, in contrast to the HBA1C
measure that captures information on glucose bound to hemoglobin RBCs for the past 3 months,
suggests that we cannot speculate on the relative severity of GDM in our cohort.
Maternal change in BMI over the course of the study (most likely weight gain) positively
confounds the relationship between GDM and lipid outcomes, which means that because we
failed to adjust for BMI changes during pregnancy we may have overestimated the association
between GDM and blood lipids. Clinical history of familial hypercholesterolemia would
predispose a woman to have elevated lipid levels, especially if she was prediabetic prior to her
pregnancy, and therefore likely to develop GDM. This means that because we failed to adjust for
familial hypercholesterolemia, the association between GDM and blood lipids would be biased
away from the null. Lastly, a high-fat maternal diet both before and throughout the course of the
pregnancy is positively associated with GDM and future metabolic disease risk. By not adjusting
for maternal diet over the course of the study our results are likely biased away from the null.
Given that GDM and abnormal lipids fall under an umbrella of metabolic risk factors,
one must consider the possibility of reverse causality, or, a third common cause affecting the
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association between GDM and lipid levels such that both exposure and outcome behave as a
confounders of each other.
9.5.

Cross Sectional Limitations
Simultaneous assessment of GDM and fasting/3hr maternal lipids at baseline creates

several cross-sectional limitations for our study.
First, the fact that both GDM status and maternal lipids are assessed at the same point at
baseline, makes it unclear whether GDM precedes or is caused by high maternal blood lipids. In
other words, a reverse causal mechanism is possible where the high lipids resulting from other
metabolic comorbidities and risk factors can lead to the development of gestational diabetes. It is
equally possible for women who have GDM and elevated blood lipids to be put on medically
prescribed dietary interventions that would underestimate the causal effects of GDM. Lastly, the
survivor bias of women dying from severe levels of GDM exposure, and therefore being
unavailable to participate in the study, would underestimate the association between GDM and
maternal and cord blood lipid outcomes.
9.6.

Generalizability
The results of this study may apply for other populations of pregnant women with

singleton pregnancies and who are at risk for metabolic syndrome/disorders. Generalizability of
these results is possible if the biologic mechanism that describes how GDM affects
cardiovascular risk is similar across women of different socioeconomic status and ethnicity,
among other factors.
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CHAPTER 10
SIGNIFICANCE
Few studies have evaluated the changes that occur in TG, HDL, LDL, and total
cholesterol levels during the diabetic pregnancy. Gestational diabetes is identified as a precursor
of cardiovascular and metabolic disease in both mother and child (46). In our study, we observed
small differences in blood lipids between women with GDM and women without GMD.
However, it is possible that studies with ample power, greater sampling variability, information
on diabetic risk prior to pregnancy, information management of GDM during pregnancy, and
limited dropout could evidence more marked differences. Furthermore, the inexplicable results
from this study indicate that more research is needed to understand both the physiology of
pregnancy complications and how to prevent metabolically adverse in utero exposures. Studies
with larger samples that passively collect extensive information on covariates via hospital
records and physician visits and are assiduous to avoid loss-to-follow-up are required to
effectively address this research question.
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CHAPTER 11
HUMAN SUBJECTS
The Baystate GDM & Lipid Metabolism Study was approved by the Institutional Review
Boards of the University of Massachusetts Amherst and Baystate Medical Center. All
participants of the study were required to sign an informed consent form which affirmed their
understanding of voluntary participation, with no impact on their medical care at Baystate.
All efforts are made to ensure that confidential information remains protected. Dataset
identifiers have been removed in accordance with HIPAA law, and information is only shared
with those involved in the study.
Minor discomfort and infection associated with providing repeated blood samples (rare)
was offset by the benefits of subjects contributing to future research and being informed of their
lipid level values. In order to boost the post-partum lipids follow-up visit, investigators offered
each woman $25 when she came to the clinic.
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CHAPTER 12
PERMISSION TO ACCESS DATA
Collaborating Baystate health professionals and UMass Amherst researchers have
provided authorization to access data for the Baystate GDM & Lipid Metabolism: 2007-2009
Study. Namely, Dr. Glenn Markenson, Chief of the Maternal and Fetal Medicine at Baystate
Medical Center, and Dr. Lisa Chasan-Taber, dedicated researcher and Professor at UMass
Amherst, have facilitated the exploration of this topic.
Both Institutional Review Boards of UMass and Baystate have approved this project in
the past, providing relatively easy access to the data. Appropriate paperwork and formalities
were filled out before the end of 2011 and submitted in accordance with Baystate requirements.
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Figure 1: Study Design: Baystate GDM and Lipid Metabolism Study, 2007
2007-200
2009

Fig.1. GDM and antenatal maternal lipids were assessed simultaneously at 24
24-28
28 weeks
gestation, while postpartum lipids were assessed 66-8 weeks post-pregnancy.
pregnancy. Cord blood lipids
were obtained at delivery. The study is thus comprised of both cross
cross-sectional
sectional and prospective
components.
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